A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of SKB518 in Patients With Lung Cancer
Latest Information Update: 17 Jun 2025
At a glance
- Drugs SKB 518 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Kelun Pharmaceutical Research Institute
Most Recent Events
- 17 Jun 2025 New trial record